Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
  • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
  • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
  • C07C65/26—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic containing rings other than six-membered aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
  • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
  • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
  • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C255/00—Carboxylic acid nitriles
  • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
  • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C255/00—Carboxylic acid nitriles
  • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
  • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
  • C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
  • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
  • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
  • C07C311/46—Y being a hydrogen or a carbon atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C317/00—Sulfones; Sulfoxides
  • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
  • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
  • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
  • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
  • C07C317/40—Y being a hydrogen or a carbon atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
  • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
  • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
  • C07C323/40—Y being a hydrogen or a carbon atom
  • C07C323/42—Y being a carbon atom of a six-membered aromatic ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C327/00—Thiocarboxylic acids
  • C07C327/38—Amides of thiocarboxylic acids
  • C07C327/48—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to carbon atoms of six-membered aromatic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2601/00—Systems containing only non-condensed rings
  • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
  • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2602/00—Systems containing two condensed rings
  • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
  • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Definitions

• BENZAMIDES This invention relates to therapeutically useful benzamide derivatives, to processes for their preparation, to pharmaceutical compositions containing them, and to methods for their use.
• R represents a straight- or branched-chain alkyl group containing up to about 4 carbon atoms
• R 2 represents a straight- or branched-chain alkyl group containing from about 2 to about 15, preferably 2 to 12, carbon atoms or a mono-, bi- or tricycloalkyl group containing up to
• R represents an optionally substituted phenyl, naphthyl or heterocyclyl group, preferably a 5-, 6- or 7-membered heterocyclyl group containing one or more hetero atoms selected from oxygen, sulphur and nitrogen atoms, the optional substituents being one or more substituents selected from halogen atoms, alkyl groups which may carry one or more halogen atoms, and from aryl, arylalkyl, alk ⁇ xy, aryloxy, alkylthio, arylthio, alkoxycarbonyl, aryloxycarbonyl, alkanoyl, aroyl, alkylsulphonyl, arylsulphonyl, alkylsulphinyl, arylsulphinyl, hydroxy, hydroxyalkyl, formyl, alkanoyla ino, aroylamino, cyano and nitro groups, and from amino, carbamoyl and
• Especially important compounds of the invention include those wherein at least one of the symbols has a value selected from the following:-
• R represents a methyl group
• R 2 represents a propyl, butyl, nonyl, dodecyl, cyclohexyl, 8,9,10-trinorbornyl or, more especially, cyclopentyl group
• R 3 represents an optionally substituted pyrazinyl, pyrimidinyl, isoxazolyl, preferably pyridyl group, or an N-oxide thereof, or an optionally substituted phenyl group; the other symbols being as hereinbefore defined.
• 6-positions are especially useful.
• R J represents a substituted heterocyclyl group
• compounds wherein said heterocyclyl group is substituted on one or both of the positions next to the point of attachment to the rest of the molecule are especially useful. Individual compounds of especial importance .
• the compounds of general formula I and their pharmaceutically acceptable salts exhibit pharmacological activity and accordingly are of use for the preparation of pharmaceutical compositions and in the treatment of humans and other animals. More especially, they are cyclic AMP phosphodiesterase inhibitors, in particular type IV cyclic AMP phosphodiesterase inhibitors, and thus the present invention provides compounds of general formula I and their pharmaceutically acceptable salts, and compositions containing compounds of general formula I and their pharmaceutically acceptable salts, which are of use in a method for the treatment of a human or animal patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of cyclic AMP phosphodiesterase, for example, they are useful as bronchodilators and asthma-prophylactic agents and agents for the inhibition of eosinophil accumulation and of the function of eosinophils, e.g.
• inflammatory airways disease especially reversible airway obstruction or asthma
• other diseases and conditions characterised by, or having an aetiology involving, morbid eosinophil accumulation.
• inflammatory diseases such as atopic dermatitis, urticaria, allergic rhinitis, psoriasis, rheumatic arthritis, ulcerative colitis, Crohn's disease, adult respiratory distress syndrome and diabetes insipidus
• other proliferative skin diseases such keratosis and various types of dermatitis
• conditions associated with cerebral metabolic inhibition such as cerebral senility, ulti-infarct dementia, senile dementia (Alzheimer's disease) , and memory impairment associated with Parkinson's disease
• neuroprote ⁇ tant activity such as cardiac arrest, stroke, and intermittent
• Compounds within the scope of the present invention exhibit positive pharmacological activities as demonstrated by the following tests which are believed to correlate to pharmacological activity in humans and other mammals.
• Compounds of the invention at concentrations from about 10 -9M up to about 10-5M produced about 50% inhibition of porcine aorta cyclic AMP phosphodiest ⁇ erase.
• Compounds of the invention at concentrations of about 10 -7M to about 10-4M produced about 50% relaxation of guinea-pig tracheal strips, which had been contracted by treatment with spasmogens such as hista ine and carbachol.
• Compounds of the invention at concentrations from about 10 -8M up to about 10-5M produced about 50% inhibition of superoxide generation from eosinophils harvested from the peritoneal cavities of guinea-pigs.
• Compounds of the invention at oral doses from about 1 to about 50 mg/kg administered 1 hour before challenge inhibited by about 50% ovalbumin- or PAF- induced hyperreactivity in guinea-pigs.
• Bronchorelaxant activity was measured in in vivo tests in the anaesthetised guinea-pig according to the method of Dixon and Brodie [J. Physiol., £9_, 97-173, (1903)] in which the effects on histamine-induced - 13 - bronchospasm and mean arterial blood pressure were. determined.
• Nebulised aerosols generated from aqueous solutions of compounds of the invention were each administered for one minute to the anaesthetised guinea-pigs.
• dry powder formulations made up from compounds of the invention and lactose were blown into the airways of the anaesthetised guinea-pigs.
• Compounds of the invention produced from about 30% up to about 90% decrease in bronchospasm when administered at effective doses of about 20-80 ⁇ g, without any significant effect on blood pressure.
• Compounds of the invention as oral doses of about 1 to about 50mg/kg, administered one hour before challenge, inhibited by at least 50% ovalbumin-induced eosinophilia in guinea-pigs, which is measured 24 hours after challenge.
• compounds of the invention Administered at doses of about 1 to about 50mg/kg orally or parenterally or at doses of about 20 to about 500 ⁇ g intratracheally, compounds of the invention inhibit PAF or ovalbumin-induced microvascular leakage (measured using fluorescein isothiocyanate dextran) by up to 100% in guinea-pigs.
• compounds of general formula I wherein R ⁇ , ⁇ 3 R * and R are as hereinbefore defined and Z represents an oxygen atom
• Z represents an oxygen atom
• compounds of general formula II hereinafter depicted, wherein R 1 and R2 are as hereinbefore defined and X "" * 1" represents a halogen, e.g. bromine or, preferably, chlorine atom, with compounds of the general formula:-
• R 3 i.s as hereinbefore defined, preferably in the presence of a base, for example an alkali metal hydroxide or carbonate, e.g. sodium hydroxide or carbonate, an alkali metal hydride, e.g. sodium hydride, or an amine, preferably a tertiary amine, e.g. triethylamine or pyridine, optionally in an inert solvent, for example dichloromethane, dimethylfor - amide, or an ether, e.g. diethyl ether or tetrahydro- furan, preferably at a temperature from 0°C to the reflux temperature or at the melting point of the reaction mixture.
• a base for example an alkali metal hydroxide or carbonate, e.g. sodium hydroxide or carbonate, an alkali metal hydride, e.g. sodium hydride, or an amine, preferably a tertiary amine, e.g. trieth
• compounds of general formula I are prepared by the reaction of compounds of general formula IV hereinafter depicted, wherein R 1, R3 and Z are as hereinbefore defined, with compounds of the general formula:-
• X represents a halogen, preferably bromine, atom, preferably in the presence of a base, for example an alkali metal hydride, e.g. sodium hydride, an alkali metal hydroxide or carbonate, e.g. sodium hydroxide or carbonate, or an amine, preferably a tertiary amine, e.g. triethylamine cr pyridine, optionally in an inert solvent, for example dichloromethane, dimethylformamide, or an ether, e.g. diethyl ether or tetrahydrofuran, preferably at a temperature from 0°C to the reflux temperature.
• a base for example an alkali metal hydride, e.g. sodium hydride, an alkali metal hydroxide or carbonate, e.g. sodium hydroxide or carbonate, or an amine, preferably a tertiary amine, e.g. triethylamine cr pyridine,
• compounds of general formula I are prepared by interconversion of other compounds of general formula I.
• compounds of general formula I wnerem R 1, R2 and R3 are as hereinbefore defined and Z represents a sulphur atom are prepared from compounds of general formula I wherein R 1, R2 and R3 are as hereinbefore defined and Z represents an oxygen atom, fcy reaction with phosphorus pentasulphide or 2,4-bis(4- methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4- disulphide, preferably in a solvent such as pyridine or toluene, and preferably at a temperature from 0°C to the reflux temperature.
• a solvent such as pyridine or toluene
• R 3 represents an oxygen atom and R contains an alkylsulphonyl, arylsulphonyl alkylsulphinyl or arylsulphinyl group are prepared by the oxidation of compounds of general formula I wherein R 1 and R2 are as hereinbefore defined, Z represents an oxygen atom and
• R" contains an alkylthio or arylthio group, preferably by means of reaction with a peroxyacid, e.g. 3-chloro- perbenzoic acid, preferably in an inert solvent, e.g. dichloromethane, preferably at or near room temperature.
• a peroxyacid e.g. 3-chloro- perbenzoic acid
• an inert solvent e.g. dichloromethane
• compounds of general formula I wherein R 1, R2 and Z are as hereinbefore defined, Z preferably being an oxygen atom, and R 3 contains a hydroxymethyl group are prepared by the reduction of compounds of general formula I wherein R 1 , R2 and Z are as hereinbefore defined and R 3 contains an aryloxycarbonyl or, preferably, alkoxycarbonyl group, preferably by means of reaction with an alkali metal borohydride, preferably in an inert solvent, e.g. tetrahydrofuran, preferably at or near room temperature.
• R 3 preferably being an oxygen atom, and R contains a formyl group are prepared by the oxidation of compounds of general formula I wherein R 1, R2 and Z are as hereinbefore defined and R 3 contains a hydroxymethyl group, preferably by means of reaction with manganese dioxide, preferably in an inert solvent, e.g. dichloromethane, preferably at or above room temperature, more especially at the reflux temperature.
• an inert solvent e.g. dichloromethane
• R 3 preferably being an oxygen atom, and R contains an amino group are prepared by the reduction of compounds of general formula I wherein R 1, R2 and Z are as
• R contains a nitro group, preferably by means of reaction with iron in acidic conditions, e.g. in acetic acid, preferably at or above room temperature, more especially at the reflux temperature.
• compounds of general formula I wherein R 1, R"° and Z are as hereinbefore defined, Z preferably being an oxygen atom, and R 3 contains an alkanoylamino or aroylamino group are prepared from compounds of general formula I wherein R1, R2 and Z are
• R contains an amino group, preferably by means of reaction with the appropriate acid halide or acid anhydride, optionally in an inert solvent, and preferably at a temperature from 0°C to the reflux temperature.
• N-oxides of compounds of general formula I wherein R 1, R2 and Z are as hereinbefore defined, Z preferably being an oxygen atom, and R 3 represents a heterocyclyl group contai.ni ⁇ ng one or more nitrogen ring atoms, are prepared by the oxidation of compounds of general formula I wherein R ,
• R 2 and Z are as herei.nbefore defined and R3 represents a heterocyclyl group containing one or more nitrogen ring atoms, preferably by means of reaction with a mixture of hydrogen peroxide and an organic acid, e.g. acetic acid, preferably at or above room temperature at
• salts the counter ions of which are relatively innocuous to the animal organism when used in therapeutic doses so that the beneficial pharmaceutical properties of the parent compounds of general formula I are not vitiated by side-effects ascribable to those counter ions.
• Suitable acid addition salts for use in pharmaceuticals may be selected from salts derived from inorganic acids, for example hydrohalides, e.g.
• hydrochlorides and hydrobromides phosphates, sulphates and nitrates, and organic acids, for example oxalates, lactates, tartrates, acetates, salicylates, citrates, propionates, succinates, fumarates, maleates, methylene-bis- ⁇ -hydroxynaphthoates, gentisates, esylates, isethionates and di- ⁇ -toluoyltartrates.
• organic acids for example oxalates, lactates, tartrates, acetates, salicylates, citrates, propionates, succinates, fumarates, maleates, methylene-bis- ⁇ -hydroxynaphthoates, gentisates, esylates, isethionates and di- ⁇ -toluoyltartrates.
• acid addition salts of compounds of formula I are prepared by reaction of the parent compounds of formula I with the appropriate acid, by the application or adaptation of known methods.
• Alkali and alkaline earth metal salts are also suitable for use in pharmaceuticals, especially sodium salts.
• alkali and alkaline earth metal salts are prepared by reaction of the parent compounds of formula I with the appropriate base, by the application or adaptation of known methods.
• sodium salts can conveniently be prepared by reaction with sodium hydride.
• salts of compounds of formula I are useful for the purposes of purification of the parent compounds of formula I, for example by exploitation of the solubility differences between the salts and the parent compounds, by techniques well known to those skilled in the art.
• the parent compounds of formula I can be regenerated from their salts by the application or adaptation of known methods.
• parent compounds of general formula I can be regenerated from their acid addition salts by treatment with an alkali, e.g. aqueous sodium bicarbonate solution or aqueous ammonia solution.
• an alkali e.g. aqueous sodium bicarbonate solution or aqueous ammonia solution.
• parent compounds of general formula I can be regenerated from their alkali and alkaline earth metal salts by treatment with an acid, e.g. hydrochloric acid.
• Such isomers can be separated from their mixtures, by the application or adaptation of known methods, for example chromatographic techniques, or they may be separately prepared from the appropriate isomers of their intermediates, for example by the application or adaptation of methods described herein.
• the starting materials and intermediates can be prepared by the application or adaptation of known methods, for example methods as described in the Reference Examples or their obvious chemical equivalents.
• compounds of formula II can be prepared from compounds of general formula Va, hereinafter depicted, wherein R 1 and R2 are as hereinbefore defined, by the application or adaptation of known methods for the preparation of acid halides from carboxylic acids.
• R 1 and R2 are as hereinbefore defined
• the reaction can be carried out by means of thionyl chloride.
• Co pounds of formula Va can be prepared by the oxidation of compounds of general formula VI, hereinafter depicted, whereinafter depicted, wherein Rl and R2 are as hereinbefore defined, e.g. by means of reaction with potassium permanganate, or with a mixture of sulphamic acid and sodium chlorite in acetic acid.
• R 2 OH VIII wherein R ⁇ is as hereinbefore defined, preferably in the presence of a compound such as diisopropyl azodicarboxylate.
• N-(2-acetylphenyl)-3-cyclopentyloxy-4-methoxybenzamide m.p. 126-127°C
• N-(2-hydroxyphenyl)-3-cyclopentyloxy-4-methoxybenz ⁇ amide m.p. 169-171°C
• EXAMPLE 8 Compounds AO.AY.BC.BG.BL.BO.BS.BX.AX.AZ.AW.BV and BW
• a suspension of sodium hydride (60% dispersion in oil; 2.2g) in dry tetrahydrofuran (25ml) at 15-20°C was treated portionwise with a solution of 4-amino-3,5- dichloropyridine (4.5g; prepared as described in Reference Example 5) in dry tetrahydrofuran (40ml) , with cooling.
• the mixture was stirred for a further 30 minutes, and then it was cooled to 10°C and treated with a solution of 3-cyclopentyloxy-4-methoxybenzoyl chloride (6.4g) in dry tetrahydrofuran (40ml), dropwise, during 45 minutes at 10°C.
• Acetic anhydride (10ml) was treated with N-(2,6-dichloro-4-aninophenyl)-3-cyclopentyloxy-4- methoxybenzamide (0.8g; prepared as described in Example 11) , and the reaction mixture was stirred for 2 hours and left to stand overnight. It was then poured into water (100ml) , and extracted with ethyl acetate (100ml) and then with dichloromethane (100ml) . The organic extracts were combined, dried over magnesium sulphate, and evaporated, to give N-(4-acetylammo-2,6-dichlorophenyl)-3-cyclopentyloxy- 4-methoxybenzamide (0.4g), m.p. 250-252°C [Elemental analysis:- C,57.6;H,5.05;N,6.3;C1,16.1%; calculated:- C,57.5;H,5.1;N,6.4;C1,16.2%].
• REFERENCE EXAMPLE 2 A stirred saturated aqueous solution of potassium permanganate (100ml) was treated with 3-cyclopentyloxy- 4-methoxybenzaldehyde (7.4g; prepared as described hereinbefore in Reference Example 1) and sodium carbonate (3.4g) and the mixture was stirred at 50°C for 1 hour, and then cooled to room temperature. The reaction mixture was acidified by treatment with concentrated hydrochloric acid and then it was treated with aqueous sodium bisulphite solution until a colourless solution was obtained. The reaction mixture was extracted with dichloromethane (2x100ml) and the organic extracts were dried over magnesium sulphate and concentrated.
• REFERENCE EXAMPLE 8 A stirred suspension of 3-hydroxy-4-methoxybenz- aldehyde (50g) in water (200ml) at between 0 and 5°C was treated dropwise with an aqueous solution of sodium hydroxide (200ml;20%w/v) , followed at between 0 and 5°C by benzoyl chloride (38ml) . The reaction mixture was stirred at between 0 and 5°C for 1 hour and then it was allowed to warm to room temperature and was stirred for a further period of 2 hours.
• sodium hydroxide 200ml;20%w/v
• benzoyl chloride 38ml
• REFERENCE EXAMPLE 11 By proceeding in a manner similar to that described in Example 8, but using 3-benzoyloxy-4- methoxybenzoyl chloride (prepared as described in Reference Example 10) and 4-amino-3,5-dichloropyridine (prepared as described in Reference Example 4) as starting materials, there was prepared N-(3,5-dichloro- pyrid-4-yl)-3-benzoyloxy-4-methoxybenzamide, m.p. 191-192°C.
• REFERENCE EXAMPLE 14 By proceeding in a manner similar to that described in Reference Example 3, but using the appropriate quantities of the corresponding benzoic acid derivatives, prepared as described hereinbefore in Reference Example 13, there were prepared:- 3-(exo)-8,9,10-trinorbornyl-2-oxy-4-methoxybenzoyl chloride;
• the present invention also includes within its scope pharmaceutical formulations which comprise at least one of the compounds of formula I or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier or coating.
• compounds of the present invention may be administered parenterally, rectally or orally, but they are preferably administered by inhalation.
• compositions containing compounds of the invention and pharmaceutically acceptable salts thereof may be prepared by conventional means.
• compounds of the invention and pharmaceutically acceptable salts thereof may be dissolved or suspended in a suitable carrier for use in a nebuliser or a suspension or solution aerosol, or may be absorbed or adsorbed onto a suitable solid carrier for use in a dry powder inhaler.
• Solid compositions for oral administration include compressed tablets, pills, powders and granules.
• one or more of the active compounds is, or are, admixed with at least one inert diluent such as starch, sucrose or lactose.
• the compositions may also comprise, as is normal practice, additional substances other than inert diluents, e.g. lubricating agents, such as magnesium stearate.
• Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs containing inert diluents commonly used in the art such as water and liquid paraffin. Besides inert diluents such compositions may comprise adjuvants, such as wetting and suspending agents, and sweetening, flavouring, perfuming and preserving agents.
• the compositions according to the invention for oral administration also include capsules of absorbable material such as gelatin, containing one or more of the active substances with or without the addition of diluents or excipients.
• compositions according to the invention for parenteral administration include sterile aqueous, aqueous-organic, and organic solutions, suspensions and emulsions.
• organic solvents or suspending media are propylene glycol, polyethylene glycol, vegetable oils such as olive oil and injectable organic esters such as ethyl oleate.
• the compositions may also contain adjuvants such as stabilising, preserving, wetting, emulsifying and dispersing agents. They may be sterilised, for example, by filtration through a bacteria-retaining filter, by incorporation in the compositions of sterilising agents, by irradiation or by heating. They may also be manufactured in the form of sterile solid compositions, which can be dissolved in sterile water or some other sterile injectable medium immediately before use.
• Solid compositions for rectal administration include suppositories formulated in accordance with known methods and containing at least one compound of formula I.
• compositions of the invention may be varied, it being necessary that it should constitute a proportion such that a suitable dosage shall be obtained. Obviously, several unit dosage forms may be administered at about the same time.
• the dose employed will be determined by the physician, and depends upon the desired therapeutic effect, the route of administration and the duration of the treatment, and the condition of the patient. In the adult, the doses are generally from about 0.001 to about 50, preferably about 0.001 to about 5, mg/kg body weight per day by inhalation.
• Composition Examples illustrate pharmaceutical compositions according to the present invention.
• N-(2,6-difluorophenyl)-3-cyclopentyloxy-4- methoxybenzamide (l.Og) (mean particle size 3.5 microns) and lactose (mean particle size 72 microns) were blended together for 30 minutes in a mechanical shaker/mixer.
• the resulting blend was filled, to a fill weight of 25mg, into No.3 hard gelatine capsules, to give a product suitable for use, for example, with a dry powder inhaler.
• N-(3,5-dichloropyrid-4-yl)-3-cyclopentyloxy-4- methoxybenzamide (l.Og) (mean particle size 3.5 microns) and lactose (mean particle size 72 microns) were blended together for 30 minutes in a mechanical shaker/mixer.
• the resulting blend was filled, to a fill weight of 25mg, into No.3 hard gelatine capsules, to give a product suitable for use, for example, with a dry powder inhaler.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pyridine Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
• Body Structure For Vehicles (AREA)
• Hydrogenated Pyridines (AREA)

Applications Claiming Priority (4)

Publications (1)

Family

ID=26298343

Family Applications (3)

Family Applications Before (1)

Family Applications After (1)

Country Status (20)

Families Citing this family (110)

Family Cites Families (3)

• 1992
  • 1992-01-27 IE IE920247A patent/IE71647B1/en not_active IP Right Cessation
  • 1992-01-28 HU HU9302199A patent/HUT64942A/hu unknown
  • 1992-01-28 NZ NZ241427A patent/NZ241427A/en unknown
  • 1992-01-28 IL IL10078892A patent/IL100788A/xx not_active IP Right Cessation
  • 1992-01-28 AT AT95106899T patent/ATE165334T1/de not_active IP Right Cessation
  • 1992-01-28 EP EP95106899A patent/EP0669311B1/de not_active Expired - Lifetime
  • 1992-01-28 ES ES92300726T patent/ES2081563T3/es not_active Expired - Lifetime
  • 1992-01-28 AT AT92300726T patent/ATE132134T1/de not_active IP Right Cessation
  • 1992-01-28 TW TW081100612A patent/TW274541B/zh active
  • 1992-01-28 WO PCT/GB1992/000153 patent/WO1992012961A1/en active IP Right Grant
  • 1992-01-28 EP EP92903462A patent/EP0569414A1/de active Pending
  • 1992-01-28 JP JP4503280A patent/JP2664538B2/ja not_active Expired - Lifetime
  • 1992-01-28 CZ CS931528A patent/CZ281894B6/cs unknown
  • 1992-01-28 DK DK92300726.4T patent/DK0497564T3/da active
  • 1992-01-28 DE DE69225245T patent/DE69225245D1/de not_active Expired - Lifetime
  • 1992-01-28 CA CA002101423A patent/CA2101423C/en not_active Expired - Lifetime
  • 1992-01-28 DE DE69207017T patent/DE69207017T2/de not_active Expired - Lifetime
  • 1992-01-28 AU AU11881/92A patent/AU664694B2/en not_active Ceased
  • 1992-01-28 MX MX9200344A patent/MX9200344A/es unknown
  • 1992-01-28 EP EP92300726A patent/EP0497564B1/de not_active Expired - Lifetime
  • 1992-01-28 SK SK809-93A patent/SK80993A3/sk unknown
• 1993
  • 1993-07-27 FI FI933357A patent/FI933357A/fi unknown
  • 1993-07-27 NO NO93932701A patent/NO932701L/no unknown
• 1995
  • 1995-06-30 HU HU95P/P00720P patent/HU211679A9/hu unknown
  • 1995-12-28 GR GR950402648T patent/GR3018544T3/el unknown
• 1996
  • 1996-02-21 AU AU45651/96A patent/AU4565196A/en not_active Abandoned

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events